Corporate Governance

St. Louis – October 02, 2026 -- DOOR (OTC: LTCH) has finalized a settlement with the U.S. Securities and Exchange Commission, closing a four-year investigation into legacy revenue recognition and key performance indicator practices with a $1.0 million civil penalty payable in quarterly installments.

SEC closes investigation that began in 2022

The SEC approved the previously disclosed settlement, which the Company first announced in principle on October 02, 2026. DOOR consented to an administrative order without admitting or denying the regulator's findings.

Company filed seven years of restated financial statements

Since late 2024, DOOR has filed seven years of financial statements, including restated prior periods, becoming current with its SEC reporting obligations in February 2026 for the first time since mid-2022.

Armonk, N.Y. – October 02, 2026 -- IBM has elected Frank Baker, 53, Co-founder and Managing Partner of Siris Capital Group, to its board of directors, effective October 02, 2026.

Siris Capital has deployed more than $9 billion in equity across tech and data-focused companies

Baker oversees Siris' portfolio and leads its investment strategy, focusing on value creation in established technology firms with mission-critical products navigating technological shifts.

IBM CEO Arvind Krishna cites Baker's strategy-driven mindset as key to shareholder value

Krishna said the company is excited to welcome Baker to the board, adding that his expertise and leadership will strengthen IBM's business as it advances enterprise-wide technology transformation for clients.

Southlake, Texas – October 01, 2026 -- Sabre Corporation (NASDAQ: SABR) has elected Rochelle Boas as Executive Vice President – Chief Legal and Administrative Officer, effective immediately, expanding her mandate beyond the Legal organization to oversee the company's People Team.

Boas gains oversight of HR as Chief People Officer Dave Medrano now reports to her

Under the restructuring, Dave Medrano, Sabre's Chief People Officer, will report directly to Boas, consolidating the travel technology company's legal and human resources functions under a single executive.

Boas joined Sabre in 2024 as Chief Legal Officer and sits on the executive leadership team

Boas has served as Sabre's Executive Vice President – Chief Legal Officer since 2024 and will continue to lead the Legal organization alongside her new administrative responsibilities.

Birkirkara – October 01, 2026 -- Gentoo Media Inc. has called an Extraordinary General Meeting of Shareholders for 2 November 2026 in Stockholm to approve a capital structure overhaul that would pave the way for a directed share issue fully underwritten by three of its largest shareholders.

Board seeks to raise authorized Common Stock to 250 million shares and create a new Class Z class

The Board of Directors is proposing a Third Amended and Restated Certificate of Incorporation that would lift authorized Common Stock from 200,000,000 to 250,000,000 shares, $0.001 par value each, while creating an additional class of 100,000,000 shares designated Class Z Common Stock. As of the notice date, Gentoo Media had 134,707,976 shares of Common Stock outstanding, each carrying one vote.

Birkirkara, Malta – October 01, 2026 -- Gentoo Media Inc. has locked in commitments worth EUR 100 million to refinance its EUR 91.5 million senior secured bonds maturing 18 December 2026, combining a new EUR 50 million term loan with a fully underwritten EUR 50 million share issue.

San Diego – October 01, 2026 -- Halozyme Therapeutics (Nasdaq: HALO) has appointed James "Jim" Daly to its Board of Directors, returning a veteran biopharmaceutical commercial executive to help steer the company's drug-delivery technology expansion.

Daly rejoins board after prior tenure, bringing three decades of launch experience

Daly previously served on Halozyme's board and has held senior commercial leadership roles at Incyte Corporation, Amgen and Glaxo Wellcome/GlaxoSmithKline. He was Executive Vice President and Chief Commercial Officer of Incyte from 2012 to 2015, following a decade at Amgen where he most recently served as Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Earlier, he spent more than 16 years at Glaxo Wellcome/GlaxoSmithKline, including as Senior Vice President and General Manager of the U.S. respiratory business.

Chicago – – October 01, 2026 -- Cars.com Inc. (NYSE: CARS) has appointed Trent Ziegler as Chief Financial Officer-Designate, effective October 01, 2026, with formal succession to the CFO role on October 01, 2026.

Ziegler replaces Sonia Jain, who transitions to Executive Advisor through October 01, 2026

The staggered handover is designed to ensure an orderly transition of financial leadership at the automotive marketplace operator. Jain will remain available to the company in an advisory capacity for nearly five months following the formal changeover.

Hayward, Calif. – October 01, 2026 -- Ultra Clean Holdings, Inc. (Nasdaq: UCTT) appointed Alexander Davern to its Board of Directors effective October 01, 2026, adding more than three decades of industrial and technology leadership experience to its governance ranks.

Davern spent nearly 30 years at National Instruments, rising through CFO, COO and CEO roles

During his tenure at National Instruments, Davern helped scale the company's operations across more than 50 countries, gaining direct oversight of finance, operations and global expansion in a technology-manufacturing environment.

Vancouver – – September 30, 2026 -- Silvercorp Metals Inc. (TSX: SVM) (NYSE American: SVM) has extended its shareholder proxy voting deadline to September 30, 2026 at 4:00 p.m. Pacific time, after approving a further revision to a special resolution governing amendments to the Company's corporate Articles ahead of its annual general and special meeting scheduled for October 2, 2026.

Company narrows information it can demand from director nominees

Silvercorp has amended Article 16, which governs how shareholders nominate individuals for election to the Board. Having initially proposed limiting the information required to assess a nominee's independence, the Company has now gone further, removing its ability to request any nominee information beyond items specifically enumerated in Article 16, paragraph 4. A redline of the proposed changes was filed on SEDAR+ on September 29, 2026 under "Other Securityholder Documents."

Kelowna, BC – September 30, 2026 -- Doseology Sciences Inc. (CSE: MOOD, OTCQB: DOSEF, FSE: VU70) has appointed Kareem Baalbaki as interim CEO, interim CFO and director, alongside Jeremy Wright as a new board director, replacing outgoing CEO Chris Jackson and CFO Chris Cherry, who have both resigned.

Baalbaki scaled a Canadian CPG operator's revenue fifteenfold before joining Doseology

Baalbaki previously served as Chief Supply Chain Officer at Revive Superfoods, where he helped grow the frozen CPG platform's annual revenue from approximately $10 million to $150 million. The Toronto-based executive holds more than a decade of operations and supply-chain experience, including restructuring underperforming businesses and advising boards on governance and organizational design. He holds a Master of Science in International Business from the University of Lincoln in the United Kingdom.